Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BP58
- Development stage
- Preclinical
- Lead developer
- CuraTeQ Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
BP58 is a subcutaneous (S.C.) biosimilar formulation of trastuzumab being developed by CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, for the treatment of HER2-positive cancers, including breast cancer. It is designed as a biosimilar to subcutaneous trastuzumab (Herceptin SC / Herceptin Hylecta), which co-formulates the anti-HER2 monoclonal antibody trastuzumab with recombinant human hyaluronidase (rHuPH20) to facilitate subcutaneous administration and reduce infusion time. BP58 is currently in preclinical development (CMC development) and is projected to enter clinical trials in 2026.
- Other names
- trastuzumab S.C.trastuzumab subcutaneous
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on BP58.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BP58.